Russia protects strategic missiles
Russia is taking on more new armoured security vehicles designed to protect its strategic missile assets.
The MoD announced on 9 January that it had completed the development of the vehicle, called Typhoon-M.
It is to be used by the units armed with the RS-25 Yars (SS-29) mobile strategic missile. In 2016, as many as 14 Typhoon-Ms were taken on strength and 12 more will follow suite in 2017.
The Typhoon-M is intended to provide protection from diversionary teams which intend to attack the positions of the Russian nuclear-tipped mobile strategic missiles, both when deployed in the field and on
Already have an account? Log in
Want to keep reading this article?
Read this Article
Get access to this article with a Free Basic Account
- Original curated content, daily across air, land and naval domains
- 2 free stories per week
- Daily news round-up email service
- Access to all Decisive Edge email newsletters
Unlimited Access
Access to all our premium news as a Premium News 365 Member. Corporate subscriptions available.
- Original curated content, daily across air, land and naval domains
- 14-day free trial (cancel at any time)
- Unlimited access to all published premium news
More from Land Warfare
-
![Australia and Singapore open expanded training area in Queensland]()
Australia and Singapore open expanded training area in Queensland
Australia and Singapore have expanded Queensland’s Shoalwater Bay Training Area (SWBTA), adding advanced facilities and technologies to support larger, longer joint military exercises under their ongoing strategic partnership.
-
![Lockheed Martin to increase PAC-3 MSE production by 70%]()
Lockheed Martin to increase PAC-3 MSE production by 70%
The company manufactured 380 missiles in 2023 and plans to build 650 missiles per year from 2027.
-
![Canadian tech firm makes promise to increase precision and longevity of weapons]()
Canadian tech firm makes promise to increase precision and longevity of weapons
Supplied by Paradigm Shift, EPVD technology has undergone trials with the US and Canadian services.
